At this year’s American Society of Clinical Oncology (ASCO) conference in Chicago recently, there were a lot of presentations on immunotherapy to treat cancer and tailoring therapies for individuals based on genetic mutations. Abstracts from the conference were recently published on ASCO’s website. The National Cancer Institute announced on Monday plans to launch a national research study sorting cancer patients to treatment groups based on genetic mutations rather than cancer type. This study could lead to drug trials that can be implemented more quickly and possibly match patients with a better suited drug for their cancer. These newer designed studies are referred to as “basket trials”. Click on the link below to a interesting graphic from the Washington Post that illustrates the difference between conventional clinical trials and basket trials.